Background: Historically, acute hepatitis C virus (HCV) infection was treated with shorter durations of interferon-containing therapies. In the era of direct-acting antivirals (DAAs), it is unclear whether the efficacy of treatment achieved in chronic infection can be maintained with abbreviated courses of therapy during the acute phase. Methods: The sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals (SWIFT-C) is an open-label, 2-cohort clinical trial in which the first cohort assessed for the safety and efficacy of 12 weeks of sofosbuvir plus ribavirin for the treatment of acute HCV infection in participants with chronic human immunodeficiency virus type 1 (HIV-1) infection. This is a preplanned analysis of the first cohort, which had a planned accrual of 17 participants. Results: Seventeen men (11 Hispanic, 6 white, median age 45 years) were enrolled. Most (88%) had HCV genotype-1 infection and few (24%) had the favorable IL28B CC genotype. Median baseline HCV RNA was 2 280 000 IU/mL (interquartile range, 272 000-4 230 000). Ten participants (59%) achieved the primary outcome of SVR12 (90% confidence interval, 36%-78%), failing to establish noninferiority. All treatment failures were due to viral relapse (41%). There were no premature treatment discontinuations. The only factor that differed between participants who achieved SVR vs those who relapsed was ribavirin concentration at the end of treatment. Conclusion: Sofosbuvir-ribavirin for 12 weeks for the treatment of acute HCV genotype-1 infection in HIV-1-infected persons results in a high relapse rate. Preliminary studies of DAA combination therapies suggest improved response rates, although the adequate duration of therapy remains unclear. Clinical Trials Registration: NCT02128217.
Background: Historically, acute hepatitis C virus (HCV) infection was treated with shorter durations of interferon-containing therapies. In the era of direct-acting antivirals (DAAs), it is unclear whether the efficacy of treatment achieved in chronic infection can be maintained with abbreviated courses of therapy during the acute phase. Methods: The sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals (SWIFT-C) is an open-label, 2-cohort clinical trial in which the first cohort assessed for the safety and efficacy of 12 weeks of sofosbuvir plus ribavirin for the treatment of acute HCV infection in participants with chronic human immunodeficiency virus type 1 (HIV-1) infection. This is a preplanned analysis of the first cohort, which had a planned accrual of 17 participants. Results: Seventeen men (11 Hispanic, 6 white, median age 45 years) were enrolled. Most (88%) had HCV genotype-1 infection and few (24%) had the favorable IL28B CC genotype. Median baseline HCV RNA was 2 280 000 IU/mL (interquartile range, 272 000-4 230 000). Ten participants (59%) achieved the primary outcome of SVR12 (90% confidence interval, 36%-78%), failing to establish noninferiority. All treatment failures were due to viral relapse (41%). There were no premature treatment discontinuations. The only factor that differed between participants who achieved SVR vs those who relapsed was ribavirin concentration at the end of treatment. Conclusion:Sofosbuvir-ribavirin for 12 weeks for the treatment of acute HCV genotype-1 infection in HIV-1-infectedpersons results in a high relapse rate. Preliminary studies of DAA combination therapies suggest improved response rates, although the adequate duration of therapy remains unclear. Clinical Trials Registration: NCT02128217.
Authors: Liviawati S Wu; Joseph E Rower; James R Burton; Peter L Anderson; Kyle P Hammond; Fafa Baouchi-Mokrane; Gregory T Everson; Thomas J Urban; David Z D'Argenio; Jennifer J Kiser Journal: Antimicrob Agents Chemother Date: 2015-02-02 Impact factor: 5.191
Authors: S Khakoo; P Glue; L Grellier; B Wells; A Bell; C Dash; I Murray-Lyon; D Lypnyj; B Flannery; K Walters; G M Dusheiko Journal: Br J Clin Pharmacol Date: 1998-12 Impact factor: 4.335
Authors: Shauna Onofrey; Jasneet Aneja; Gillian A Haney; Ellen H Nagami; Alfred DeMaria; Georg M Lauer; Kelsey Hills-Evans; Kerri Barton; Stephanie Kulaga; Melinda J Bowen; Noelle Cocoros; Barbara H McGovern; Daniel R Church; Arthur Y Kim Journal: Ann Intern Med Date: 2015-08-18 Impact factor: 25.391
Authors: Katja Deterding; Christoph D Spinner; Eckart Schott; Tania M Welzel; Guido Gerken; Hartwig Klinker; Ulrich Spengler; Johannes Wiegand; Julian Schulze Zur Wiesch; Anita Pathil; Markus Cornberg; Andreas Umgelter; Caroline Zöllner; Stefan Zeuzem; Armin Papkalla; Kristina Weber; Svenja Hardtke; Heiko von der Leyen; Armin Koch; Dorothee von Witzendorff; Michael P Manns; Heiner Wedemeyer Journal: Lancet Infect Dis Date: 2016-10-28 Impact factor: 25.071
Authors: David Chromy; Mattias Mandorfer; Theresa Bucsics; Philipp Schwabl; Bernhard Scheiner; Caroline Schmidbauer; Maximilian Christopher Aichelburg; Peter Ferenci; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger Journal: United European Gastroenterol J Date: 2019-03-06 Impact factor: 4.623
Authors: Christine E MacBrayne; Kristen M Marks; Daniel S Fierer; Susanna Naggie; Raymond T Chung; Michael D Hughes; Arthur Y Kim; Marion G Peters; Diana M Brainard; Sharon M Seifert; Jose R Castillo-Mancilla; Lane R Bushman; Peter L Anderson; Jennifer J Kiser Journal: J Antimicrob Chemother Date: 2018-08-01 Impact factor: 5.790
Authors: Susanna Naggie; Daniel S Fierer; Michael D Hughes; Arthur Y Kim; Annie Luetkemeyer; Vincent Vu; Jhoanna Roa; Steve Rwema; Diana M Brainard; John G McHutchison; Marion G Peters; Jennifer J Kiser; Kristen M Marks; Raymond T Chung Journal: Clin Infect Dis Date: 2019-07-18 Impact factor: 20.999